Search research articles
Contact Us
Filters
Showing results (51-60 of 107) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2007
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma
Ivo Meinhold-Heerlein, Dirk Bauerschlag, Yingyao Zhou, et al.
Analytical Chemistry
|
July 14, 2025
Robust Automated Separation of Circulating Tumor Cells and Cancer-Associated Fibroblasts for Enhanced Liquid Biopsy in Breast Cancer
Hyeong Jung Woo, Paul N Rademacher, Hyun Young Shin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 17, 2020
LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial
Annette Hasenburg, Jalid Sehouli, Bjoern Lampe, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 30, 2020
Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study
Rudiger Klapdor, Peter Hillemanns, Linn Wölber, et al.
The Lancet. Oncology
|
January 22, 2013
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
Dan Stark, Matthew Nankivell, Eric Pujade-Lauraine, et al.
Oncogene
|
November 24, 2004
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential
Ivo Meinhold-Heerlein, Dirk Bauerschlag, Felix Hilpert, et al.
Gynecologic Oncology
|
November 23, 2016
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Roberto Sorio, Célia Roemer-Becuwe, Felix Hilpert, et al.
Gynecologic Oncology
|
July 21, 2019
Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study
Linn Woelber, Christine Eulenburg, Jens Kosse, et al.
The Lancet. Oncology
|
August 14, 2018
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Radoslav Chekerov, Felix Hilpert, Sven Mahner, et al.
Journal of the National Cancer Institute
|
January 26, 2015
Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study
Sven Mahner, Julia Jueckstock, Felix Hilpert, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 107) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2007
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma
Ivo Meinhold-Heerlein, Dirk Bauerschlag, Yingyao Zhou, et al.
Analytical Chemistry
|
July 14, 2025
Robust Automated Separation of Circulating Tumor Cells and Cancer-Associated Fibroblasts for Enhanced Liquid Biopsy in Breast Cancer
Hyeong Jung Woo, Paul N Rademacher, Hyun Young Shin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 17, 2020
LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial
Annette Hasenburg, Jalid Sehouli, Bjoern Lampe, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 30, 2020
Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study
Rudiger Klapdor, Peter Hillemanns, Linn Wölber, et al.
The Lancet. Oncology
|
January 22, 2013
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
Dan Stark, Matthew Nankivell, Eric Pujade-Lauraine, et al.
Oncogene
|
November 24, 2004
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential
Ivo Meinhold-Heerlein, Dirk Bauerschlag, Felix Hilpert, et al.
Gynecologic Oncology
|
November 23, 2016
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Roberto Sorio, Célia Roemer-Becuwe, Felix Hilpert, et al.
Gynecologic Oncology
|
July 21, 2019
Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study
Linn Woelber, Christine Eulenburg, Jens Kosse, et al.
The Lancet. Oncology
|
August 14, 2018
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Radoslav Chekerov, Felix Hilpert, Sven Mahner, et al.
Journal of the National Cancer Institute
|
January 26, 2015
Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study
Sven Mahner, Julia Jueckstock, Felix Hilpert, et al.
Page
of 11